Bepranemab

Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody. Bepranemab targets the central portion of tau, specifically amino acids 235 to 246. Bepranemab can be used for Alzheimer’s disease (AD) research[1][2].

Product Specifications

CAS Number

[2244960-75-4]

Product Name Alternative

UCB 0107

UNSPSC

12352203

Target

Tau Protein

Type

Inhibitory Antibodies

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/bepranemab.html

Purity

99.90

Solubility

10 mM in DMSO

Smiles

[Bepranemab]

Molecular Weight

(145.52 kDa)

References & Citations

[1]Matthew E Barton, et al. Design of a patient- and investigator-blind, randomized, placebo-controlled study to evaluate efficacy, safety, and tolerability of bepranemab, UCB0107, in prodromal to mild Alzheimer’s disease: The TOGETHER Study, AH0003. Alzheimer's & Dementia. 31 December 2021.|[2]Neațu M, et al. Monoclonal Antibody Therapy in Alzheimer's Disease. Pharmaceutics. 2023 Dec 29;16 (1) :60.